Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Target Oncol. 2019 Oct;14(5):563–575. doi: 10.1007/s11523-019-00662-4

Figure 2.

Figure 2.

Survival of EμMyc mice treated with cyclophosphamide or MLN8237. Mice each received cyclophosphamide (100 mg/kg/week via intraperitoneal injection), MLN8237 (50 mg/kg/day orally), or the combination of cyclophosphamide and MLN8237 when palpable tumors were first palpated. The control group received no treatment.